# CASE REPORT Open Access



# Addressing comprehensive complexities a striking familial hypercholesterolemia case study

Shazia Rasheed<sup>1</sup>, Ghulam Kubra<sup>1</sup>, Lubna Baqai<sup>2</sup>, Muhammad Liaquat Raza<sup>3,4,5,6\*</sup>, Fariha Hassan<sup>1</sup> and Sved Ghazi Abbas Rizvi<sup>1</sup>

### **Abstract**

**Background** Premature aortic involvement and comprehensive management strategies in familial hypercholesterolemia familial hypercholesterolemia (FH), a rare autosomal dominant genetic disorder, poses significant challenges due to its propensity for elevated low-density lipoprotein cholesterol, premature coronary heart disease, and vascular atherosclerosis.

**Case presentation** Unraveling Cardiovascular Complexities: A Striking Familial Hypercholesterolemia. This case study delves into a remarkable instance of FH in a 16-year-old female who presented with chest pain and worsening dyspnea. Diagnostic evaluation revealed distinct electrocardiographic changes, elevated troponin levels, and profound dyslipidemia. Remarkable findings on transthoracic echocardiography, computed tomography angiography, and catheterization prompted multidisciplinary interventions and demonstrated remarkable enhancements in ventricular function, mitral regurgitation, and aortic stenosis.

**Conclusion** The case study underscores the urgency of comprehensive management strategies in confronting the myriad challenges of FH, emphasizing the value of early intervention, innovative therapies, and rigorous imaging modalities for unraveling the intricate cardiovascular manifestations of this condition.

**Keywords** Familial hypercholesterolemia, Coronary artery disease, Aortic stenosis, Case report

Muhammad Liaquat Raza liaquathei@yahoo.com

## **Background**

Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C), xanthoma formation, premature coronary heart disease, and vascular atherosclerosis, primarily attributed to mutations in the LDL receptor gene [1]. FH is a rare condition, affecting only one in a million individuals [2, 3]. This disorder contributes to accelerated atherogenesis, particularly impacting the aortic system and potentially leading to aortic root narrowing [3].

Furthermore, early-onset coronary atherosclerosis resulting in ischemic heart disease imposes a substantial burden, prompting acute coronary events at a younger age. Notably, FH-associated complications encompass aortic root involvement, supravalvular aortic stenosis,



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

<sup>\*</sup>Correspondence:

<sup>&</sup>lt;sup>1</sup> Non-Invasive Cardiology at National Institute of Cardiovascular Diseases (NICVD), Rafiqui (H.J.) Shaheed Road, Karachi 75510, Pakistan

<sup>&</sup>lt;sup>2</sup> Tabba Heart Institute, Karachi, Pakistan

<sup>&</sup>lt;sup>3</sup> Al Fatima Hospital, Karachi, Pakistan

 $<sup>^4</sup>$  Department of Infection Prevention Control, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia

<sup>&</sup>lt;sup>5</sup> King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

<sup>&</sup>lt;sup>6</sup> King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi

premature coronary ostial stenosis, and a significantly elevated risk of morbidity and mortality in the youthful population [4-6].

# **Case presentation**

In this case study, we present a 16-year-old female with a confirmed diagnosis of familial hypercholesterolemia who sought emergency care due to chest pain and deteriorating dyspnea. Upon cardiac auscultation, a distinct ejection systolic murmur was detected along the right upper sternal border. Physical examination revealed cutaneous xanthomas on the hands, elbows, and legs (Fig. 1, informed written consent secured for publication). Electrocardiogram (ECG) analysis displayed inadequate progression of R waves in anterior leads, coupled with ST segment depression and T wave inversion in lateral leads. Elevated troponin I levels (17.15 ng/dL) were observed, alongside dyslipidemia characterized by total cholesterol of 569 mg/dL, HDL of 59 mg/dL, LDL-C of 484 mg/dL, and triglycerides at 129 mg/dL. Remaining laboratory parameters were unremarkable. Transthoracic echocardiography revealed severe generalized left ventricular systolic dysfunction (EF: 20%), profound secondary





Fig. 1 Cutaneous xanthelasmas on extensor surface

mitral regurgitation, and marked aortic root narrowing (Figs. 2, 3a) with mean and peak pressure gradients of 14 and 22 mmHg, respectively. Computed tomography angiography verified these findings, showcasing a thickened aortic wall with calcification in the ascending aorta. Distinct wall thickening encompassed coronary ostia and branches of the aortic arch. Aortic measurements were: Annulus 14.9 mm, Sinus 10.6 mm, STJ 11.5 mm, ascending aorta 19.8 mm, Arch 18.3 mm, descending thoracic aorta 13.2 mm, and abdominal aorta 7.8 mm (Fig. 4). Left heart catheterization demonstrated significant ostial stenosis in the left anterior descending (LAD) and right coronary arteries. After multidisciplinary consultation, the patient underwent percutaneous coronary intervention for LAD and right coronary artery (Fig. 5). Subsequent echocardiography revealed enhanced left ventricular systolic function (EF: 40%), reduced mitral regurgitation, and notably, an increased supravalvular stenosis gradient (Fig. 3b). The patient exhibited marked symptom improvement following revascularization, combined with optimized medical therapy involving high-dose statin and ezetimibe. Follow-up after 1 month indicated asymptomatic status and regular clinical monitoring.

# **Discussion**

The management of familial hypercholesterolemia encompasses diverse strategies. Robust evidence supports the effectiveness of high-dose statin therapy alongside ezetimibe for substantial LDL reduction [7]. For refractory cases, lipid apheresis and innovative proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab and evolocumab, offer promising alternatives. PCSK9 inhibitors augment LDL receptor availability, promoting enhanced LDL absorption and consequent reduction in cardiovascular risk [7]. Noninvasive imaging plays a pivotal role in evaluating cardiac and aortic involvement. Techniques encompass echocardiography, magnetic resonance imaging (MRI), and CT scans, each offering detailed insights into the heart, aorta, and coronary arteries [8]. Echocardiography gauges valvular function and blood flow, while CT scans detect coronary calcification indicative of atherosclerosis. Left heart catheterization guides treatment planning by delineating coronary involvement. Management options, tailored to disease severity and patient characteristics, span percutaneous stenting, conventional coronary artery bypass grafting, surgical interventions, and hybrid approaches [9, 10].





Fig. 2 a Parasternal long axis view showing narrowed aortic root on 2D, and b turbulence on color Doppler

# **Conclusion**

This comprehensive analysis underscores the significance of addressing cholesterol disorders in early stages to mitigate substantial morbidity and mortality.

Rigorous assessment, employing noninvasive and invasive modalities, is imperative for unraveling FH-related complications. Novel therapeutic agents warrant consideration to curtail disease progression.




**Fig. 3** a Continuous wave Doppler on TTE showing gradient across Aortic valve, **b** which increases after coronary revascularization after increasing in LV systolic function





Fig. 4 CT aortogram showing significant narrowing of aorta





**Fig. 5** Successful revascularization of ostial left anterior descending artery (LAD) and ostial right coronary artery (RCA)

### Abbreviations

CT Computed tomography ECG Electrocardiogram

FH Familial hypercholesterolemia LAD Left anterior descending

LDL-C Low-density lipoprotein cholesterol

LV Left ventricle

MRI Magnetic resonance imaging

PCSK9 Proprotein convertase subtilisin/kexin type 9

### Acknowledgements

Not applicable

### Authors' contributions

SR designed the study. SR, GK, and FH collected the data. LB and MLR was major contributor in writing of manuscript. SGAR helped in the interpretation of findings. All authors read and approved the final manuscript.

### **Funding**

There is no funding involved in this study.

### Availability of data and materials

Not applicable.

### **Declarations**

### Ethics approval and consent to participate

As per institutional guidelines (aligned with Helsinki Declaration), all studies on human subject and use of their data have been approved institutional committee of NICVD, Karachi. Informed consent secured from patients for the fair use in teaching and research.

### Consent for publication

Informed consent secured for publication and the fair use in teaching and research.

### **Competing interests**

The authors declare that they have no competing interests.

Received: 10 April 2023 Accepted: 15 April 2024 Published online: 20 April 2024

# References

- Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS et al (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34:3478–3900a
- Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA et al (2013) Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 381:1293–1301
- Qaiser S, Sheikh S, Malik MS (2012) Homozygous Familial Hypercholestrolaemia presents with supravalvular aortic stenosis. J Pak Med Assoc 62:612–614
- Loh WJ, Chan DC, Mata P, Watts GF (2022) Familial hypercholesterolemia and elevated lipoprotein(a): cascade testing and other implications for contextual models of care. Front Genet 27(13):905941. https://doi.org/10. 3389/fgene.2022.905941
- Perez de Isla L, Alonso R, Mata N, Saltijeral A, Muniz O, Rubio-Marin P et al (2016) Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler Thromb Vasc Biol. 36:2004–2010
- Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW et al (2015) The agenda for familial hypercholesterolemia:

- a scientific statement from the American Heart Association. Circulation 132:2167–2192
- Soutar AK, Naoumova RP (2007) Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 4:214–225
- El-Koofy NM, Fattouh AM, Ramadan A, Elmonem MA, Hamed DH (2022)
   Early myocardial functional abnormalities in primary dyslipidemia: clinical and echocardiographic observations in young children from a highly consanguineous population. Clin Exp Pediatr 65(8):410–416. https://doi.org/10.3345/cep.2021.00598
- Saito S, Usui A, Akita T, Ueda Y (2006) Surgery for calcific aortic stenosis in homozygous familial hypercholesterolemia. Eur J Cardiothorac Surg 29:114–116
- Yasuda T, Kawasuji M, Sakakibara N, Watanabe Y (2000) Aortic valve replacement for the calcified aorta in homozygous familial hypercholesterolemia. Eur J Cardiothorac Surg 18:249–250

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.